The 10th International Conference on Oral Iron Chelators in the Treatment of β-Thalassemia and Other Diseases and Biomed Meeting

Bibliography

• OLIVIERI NF, BRITTENHAM GM, MCLAREN CE et al: Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. N Engl. J. Med. (1998) 339:417–423.
   PubMed Web of Science ®Google Scholar
• FRAGATOU S, HANDRINOU H, RICHARDSON C, POLITIS C: Li therapy in thalassemia patients with severe iron overload: 42 months of follow-up. Proceedings of the 10th International Conference on Oral Iron Chelators in the Treatment of Thalassemia and Other Diseases and Biomed Meeting. 22–26 March 2000, Limassol, Cyprus (Abstract 8)
   Google Scholar
• AL REFAIE FN, WONKE B, HOFFBRAND AV: Deferiprone-associated myelotoxicity. Eur. J. Hematol (1994) 53:298–301.
   PubMed Web of Science ®Google Scholar
• GRADY RW, BERDOUKAS VA, RACHMILEWITZ EA, GIARDINA PJ: Combining deferiprone and desferriox-amine to optimise chelation. The Sydney Children's Hospital experience with the oral iron chelator-deferiprone. Proceedings of the 10th International Confer-ence on Oral Iron Chelators in the Treatment of Thalassemia and Other Diseases and Biomed Meeting. 22–26 March 2000, Limassol, Cyprus (Abstract 9).
   Google Scholar
• GOGTEY J, AGARWAL MB, RAJADHYAKSHA G: Deferi-prone (Kelfer-L1). A review of the Indian study over 10 years. Proceedings of the 10th International Conference on Oral Iron Chelators in the Treatment of Thalassemia and Other Diseases and Biomed Meeting. 22–26 March 2000, Limassol, Cyprus (Abstract 4).
   Google Scholar
• BERDOUKAS V, LINDEMEN R, EAGLE C et al.: The Sydney Children's Hospital experience with the oral iron chelator-deferiprone. Proceedings of the 10th Interna-tional Conference on Oral Iron Chelators in the Treatment of Thalassemia and Other Diseases and Biomed Meeting. 22–26 March 2000, Limassol, Cyprus (Abstract 6).
   Google Scholar
• NIELSEN P, ENGELHARDT R, DUERKEN M, JANKA GE, FISCHER R: Using squid biomagnetic susceptometry in the treatment of thalassemia. Proceedings of the 10th International Conference on Oral Iron Chelators in the Treatment of Thalassemia and Other Diseases and Biomed Meeting. 22–26 March 2000, Limassol, Cyprus (Abstract 12).
   Google Scholar
• TONDURY P, NIELSEN P, FISCHER R, ZIMMERMANN A, VON DER WEID N, HIRT A: Liver iron and fibrosis during long-term treatment with deferiprone in Swiss thalassaemic patients, 1998–2000. Proceedings of the 10th International Conference on Oral Iron Chelators in the Treatment of Thalassemia and Other Diseases and Biomed Meeting. 22–26 March 2000, Limassol, Cyprus (Abstract 10).
   Google Scholar
• KONTOGHIORGHES GJ, PAPATRYPHONOS A, PASHALIDIS I: Li-Deferiprone worldwide update and new strategies for improving its therapeutic efficiency. Proceedings of the 10th International Confer-ence on Oral Iron Chelators in the Treatment of Thalassemia and Other Diseases and Biomed Meeting. 22–26 March 2000, Limassol, Cyprus (Abstract 10).
   Google Scholar
• HIDER RC, KAYYALI R, EVANS P: The production of hydroxyl radicals by deferiprone-iron compounds. Proceedings of the 10th International Conference on Oral Iron Chelators in the Treatment of Thalassemia and Other Diseases and Biomed Meeting. 22–26 March 2000, Limassol, Cyprus (Abstract 52).
   Google Scholar
• RAYMOND KN, XU J, CLARKE KM et al: Multidentate hydroxypyridone iron chelators. Proceedings of the 10th International Conference on Oral Iron Chelators in the Treatment of Thalassemia and Other Diseases and Biomed Meeting. 22–26 March 2000, Limassol, Cyprus (Abstract 36).
   Google Scholar
• HIDER RC, LIU ZD, PIYAMONGKOL S: The design and properties of 'high pM' hydroxypyridin-4-ones. Proceedings of the 10th International Conference on Oral Iron Chelators in the Treatment of Thalassemia and Other Diseases and Biomed Meeting. 22–26 March 2000, Limassol, Cyprus (Abstract 54).
   Google Scholar
• LORÉAL O, GOSRIWATANA I, GUYADER D, PORTER J. BRISSOT P, HIDER RC: Determination of non-transferrin-bound iron in genetic hemochroma-tosis using a new HPLC based method. Proceedings of the 10th International Conference on Oral Iron Chelators in the Treatment of Thalassemia and Other Diseases and Biomed Meeting. 22–26 March 2000, Limassol, Cyprus (Abstract 48).
   Google Scholar
• MARX JJM, DE VALK B, ROEST M, HIDER RC: Iron absorp-tion and non-transferrin bound iron (NTBD are increased in hereditary haemochromatosis heterozygotes. Proceedings of the 10th International Conference on Oral Iron Chelators in the Treatment of Thalassemia and Other Diseases and Biomed Meeting. 22–26 March 2000, Limassol, Cyprus (Abstract 49).
   Google Scholar
• CAPPELLINI MD, CATTANEO C, CORTELEZZI A et al.: Non-transferrin-bound iron in myelodysplastic syndromes: A marker of ineffective erythropoiesis ? Proceedings of the 10th International Conference on Oral Iron Chelators in the Treatment of Thalassemia and Other Diseases and Biomed Meeting. 22–26 March 2000, Limassol, Cyprus (Abstract 16).
   Google Scholar
• GEORGIOU NA, VAN DER BRUGGEN T, OUDSHOORN M, NOTTET HSLM, MARX JJM, VAN ASBECK BS: The iron chelator deferoxamine and nucleoside analog didano-sine, synergistically inhibit 111V-1 in human mononu-clear cells. Proceedings of the 10th International Conference on Oral Iron Chelators in the Treatment of Thalassemia and Other Diseases and Biomed Meeting. 22–26 March 2000, Limassol, Cyprus (Abstract 55).
   Google Scholar